News
hema.to closes €3.7 million seed round led by Elaia Partners
In May, hema.to closed its seed round with Elaia Partners, Heal Capital, and HTGF to bring precision diagnostics to immune medicine.
Elaia Managing Partner Anne-Sophie Carrese said that the founding team’s entrepreneurial and research experience, together with hema.to’s plans to scale its go-to-market strategy, fit Elaia’s deep-tech seed investment thesis.